drugset / Trial / NCT00002940

Hydroxyurea in Treating Patients With Epstein-Barr Virus-Associated Primary CNS Lymphoma and AIDS

NCT00002940

Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of hydroxyurea in treating patients with Epstein-Barr virus-associated primary CNS lymphoma and AIDS.

Timeline

Start
1996-10
Primary completion
2002-03
Completion
2002-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydroxyurea Other / unclassified Oral

Indications